A Contract Development and Manufacturing Organization (CDMO) is the outsourcing partner behind an estimated 73%+ of FDA-approved drugs today and in 2026, the global CDMO market is worth more than $270 billion and growing fast. Whether you’re a biotech founder choosing your first manufacturing partner or a pharma executive navigating the BIOSECURE Act’s reshoring pressure, this guide breaks down exactly what a CDMO does, how it differs from a CMO or CRO, and what to look for in 2026’s tightening capacity market.
In the dynamic world of pharma and biopharma, the need to innovate the development and manufacturing of new drugs cost-effectively and at speed has become critically important. As the industry evolves, companies are constantly looking for ways to streamline operations, reduce costs, and bring innovative products to market faster — which is exactly why Contract Development and Manufacturing Organizations (CDMOs) have become fundamental to the pharma ecosystem.
What Is a CDMO?
A Contract Development and Manufacturing Organization (CDMO) is a service provider in the pharmaceutical industry that offers comprehensive services spanning drug development through manufacturing. In essence, a CDMO is a one-stop shop for pharmaceutical and biotech companies, allowing them to outsource a significant portion of their operations rather than build costly in-house infrastructure.
The term breaks down simply: “Contract” refers to the contractual agreement between the pharma company (the sponsor) and the service provider. “Development and Manufacturing” refers to the wide range of services CDMOs provide — everything from pre-formulation, formulation development, and stability studies, to method development, pre-clinical and Phase I clinical trial materials, late-stage clinical trial materials, formal stability testing, scale-up, registration batches, and full commercial production.
The Global CDMO Market in 2026
The global pharmaceutical CDMO market size is valued at USD 197.40 billion in 2025 and is predicted to increase from USD 211 billion in 2026 to approximately USD 392.67 billion by 2035, expanding at a CAGR of 7.12% from 2026 to 2035. (Source- Precedence Research)
This explosive growth trajectory reflects a fundamental transformation in pharmaceutical manufacturing, where outsourcing has evolved from a cost-optimization strategy into a strategic imperative for accessing specialized expertise, cutting-edge technologies, and flexible production capacity. The CDMO sector now stands as the backbone of biopharmaceutical innovation, enabling companies to focus internal resources on drug discovery while leveraging external partners for development and manufacturing excellence.
Four macro forces are reshaping the competitive and structural landscape of the global CDMO industry heading into the second half of this decade.
The first is the biologics and advanced therapy manufacturing wave. Monoclonal antibodies, gene therapies, cell therapies, and peptide therapeutics require capital-intensive, technically specialized manufacturing infrastructure that most sponsors cannot justify building in-house — driving sustained outsourcing demand that grows structurally with every new biologic approval.
The second is the GLP-1 peptide capacity surge. The extraordinary commercial success of semaglutide and tirzepatide has created acute fill-finish and peptide synthesis bottlenecks globally, pulling CDMO capacity toward this segment and reshaping the manufacturing strategies of sponsors across the industry.
The third is the ADC manufacturing boom. With over 300 antibody-drug conjugate candidates in clinical development as of 2025, CDMOs with high-potency API handling capabilities and conjugation platforms have become some of the most strategically valuable organizations in the sector — and one of the most capacity-constrained.
The fourth is M&A consolidation and the rise of end-to-end integrated CDMOs. Consolidation — typified by Novo Holdings’ $16.5 billion purchase of Catalent — signals a decisive shift toward end-to-end providers that combine development, scale-up, and commercial production. This trend is redrawing competitive dynamics and prompting sponsors to reassess whether specialist or integrated partners better serve their long-term manufacturing strategies.
What Does a CDMO Do?
A CDMO sits at the intersection of pharmaceutical science, engineering, regulatory expertise, and commercial manufacturing. Its core function is to accelerate a drug sponsor’s path from molecule to market by providing the development and production capabilities that most companies — particularly small and mid-sized biotechs — cannot economically build and sustain in-house.
CDMOs offer a range of services across the pharmaceutical development and manufacturing process, including:
-
API Development & Synthesis: Comprehensive small molecule and complex API development, route scouting, process chemistry, and scalable GMP manufacturing.
-
Drug Product Formulation Development: Pre-formulation studies, dosage form design, optimization, and technology transfer for solid, liquid, and injectable products.
-
Analytical Development & Validation: Method development, stability testing, impurity profiling, and full GMP validation to support regulatory filings.
-
Process Scale-Up & Optimization: Robust process development, tech transfer, and commercial-scale manufacturing readiness to ensure cost efficiency and reproducibility.
-
Clinical Supply Manufacturing: GMP production of clinical trial materials across Phase I, II, and III, including packaging, labeling, and global distribution support.
-
Sterile Fill-Finish Services: Aseptic processing, lyophilization, and injectable product manufacturing in compliance with global regulatory standards.
-
Secondary Packaging & Serialization: End-to-end packaging solutions, labeling, serialization, and supply chain compliance.
-
Regulatory Affairs & CMC Support: Strategic CMC documentation and submission support for IND, NDA, and BLA filings with the FDA, EMA, and other global regulatory authorities.
-
End-to-End Lifecycle Partnership: Engagement beginning at the IND-enabling stage through Phase I–III clinical development, regulatory approval, and commercial manufacturing, positioning the CDMO as a long-term strategic manufacturing partner.
The CDMO sector continues to grow and diversify, with an ever-increasing range of companies to choose from:
Download the full infographic here.
Essential CDMO Resources
To help with getting the most from the CDMO sector we have created a number of useful resources:
European CDMO Landscape Infographic
CDMO vs. CMO vs. CRO: What’s the Difference?
| Organization | Core Focus | Typical Scope |
|---|---|---|
| CRO (Contract Research Organization) | Research services | Early-stage R&D, pre-clinical studies, clinical trial management, regulatory affairs |
| CMO (Contract Manufacturing Organization) | Manufacturing only | Large-scale production using the sponsor’s existing formulation and process |
| CDMO (Contract Development and Manufacturing Organization) | Development + manufacturing | End-to-end support from early formulation through commercial-scale production and packaging |
In short: a CRO helps you prove a drug works; a CMO helps you make it at scale once the process is fixed; a CDMO does both — developing the formulation and process, then scaling it into commercial manufacturing under one roof.
Read CDMOs vs CROs vs CMOs: Understanding Key Services at Each Stage of Drug Development
Why Pharma Companies Use CDMOs
Developing a new drug is complex, time-consuming, and expensive. Here are the key reasons pharma and biotech companies choose to partner with CDMOs:
- Speed to market: CDMOs have the expertise and ready infrastructure to expedite development, helping sponsors reach patients faster.
- Cost savings: Outsourcing avoids the high capital expenditure of building dedicated manufacturing facilities and reduces operational overhead.
- Scalability: CDMOs offer flexible capacity, letting sponsors scale production up or down based on demand.
- Focus on core competencies: Outsourcing complex development and manufacturing frees internal teams to focus on discovery and commercialization.
- Regulatory compliance: Experienced CDMOs navigate FDA, EMA, PMDA, and other global regulatory frameworks daily.
- Access to advanced technologies: Many CDMOs offer specialized equipment and platforms — from continuous manufacturing to AI-driven process development — that would be uneconomical to build in-house.
The BIOSECURE Act and CDMO Reshoring in 2026
This is the single biggest structural shift in the CDMO landscape heading into the second half of 2026, and any sponsor evaluating outsourcing partners needs to understand it.
The BIOSECURE Act became US law on December 18, 2025, as part of the FY2026 National Defense Authorization Act (NDAA). It prohibits US federal agencies from contracting with companies that use biotechnology equipment or services from designated “biotechnology companies of concern” — a category expected to include several major China-based CDMOs and genomics firms.
Why it matters beyond federal contracts: with 79% of biopharma companies relying on at least one Chinese CDMO relationship, and an estimated $10–20 billion in annual contracts potentially in play, the ripple effects extend well past companies with direct federal funding. Commercial partners are already re-evaluating supply chains pre-emptively.
- Timeline: The official OMB “companies of concern” designation list is expected around late 2026; federal enforcement is not anticipated before late 2028.
- Commercial impact today: CDMO rates are expected to rise 5–10% annually as sponsors pre-emptively re-source capacity ahead of the designation list.
- Who benefits: US CDMOs (onshore, tariff- and BIOSECURE-insulated), EU CDMOs (quality heritage, complex modalities), and Indian CDMOs (cost and agility as the primary “plus-one” option) all stand to gain share — provided they have qualified, near-term capacity.
The practical takeaway for sponsors: switching CDMOs is not instant. It typically requires facility and process requalification and regulatory filings (e.g., a prior-approval supplement or IND amendment), which can take 12–24 months. Companies with China-linked CDMO relationships are advised to begin dual-sourcing now rather than waiting for the formal designation list.
- Read our ranking of 676 FDF CDMO manufacturing sites across Europe, which reveals the countries with the most facilities in operation.
How to choose the right CDMO for your business
Selecting the right CDMO is a critical decision that can significantly impact the success of a company’s drug development and manufacturing process. A CDMO partnership is typically a long-term strategic relationship, so fit — in size, culture, and specialization — matters as much as price.
- Industry credibility: Look for a strong track record, client references, and relevant regulatory inspection history.
- End-to-end support: Confirm the CDMO covers every stage you need, from pre-formulation through commercial production.
- Proactive risk mitigation: Robust risk-management strategies to anticipate and mitigate potential challenges.
- Project management: A proven record of delivering projects on time and within budget.
- Scalability: Ability to scale production quickly and efficiently as demand grows.
- Trustworthiness and transparency: Open communication and a demonstrated commitment to client needs.
- Geopolitical resilience: Given BIOSECURE Act dynamics, assess whether the CDMO’s supply chain and ownership structure could expose your program to future compliance risk.
- Digital maturity: AI-enabled process development and digital twin capabilities are increasingly a marker of a forward-looking partner.
In this video, David Caron SVP CMC at Ayala Pharmaceuticals explained his framework for selecting a Contract Manufacturing partner:
What Does It Cost to Work with a CDMO?
CDMO pricing varies enormously by modality, scale, and service scope, so there’s no single industry-standard rate card — but a few factors consistently drive cost:
- Modality complexity: Biologics, ADCs, and cell & gene therapies cost substantially more to develop and manufacture than small-molecule oral solid doses.
- Capacity scarcity: Constrained segments — GLP-1 peptides, sterile fill-finish, viral vectors — command premium pricing due to limited qualified capacity.
- Batch scale and campaign length: Clinical-scale batches typically carry higher per-unit costs than commercial-scale runs.
- Market-wide pricing pressure: CDMO rates are projected to rise 5–10% annually through 2026–2028 as BIOSECURE-driven re-sourcing tightens available capacity.
Sponsors should request detailed, phase-specific quotes early and build in contingency for rate increases on multi-year commercial agreements, particularly in capacity-constrained modalities.
The Future of CDMOs in the Pharma Industry
Several trends will continue to shape the CDMO sector through the rest of this decade:
- Technological capability as a differentiator: AI-enabled process development, digital twins, and connected manufacturing platforms are becoming key selection criteria for sponsors
- Specialization over generalization: As therapeutic areas grow more complex, specialized CDMOs offering deep expertise in specific modalities — peptides, ADCs, cell and gene therapy — are gaining share over generalists
- Geopolitical realignment: The BIOSECURE Act is accelerating a structural shift of manufacturing capacity toward the US, EU, and India, away from China-based providers
Frequently Asked Questions
What does CDMO stand for?
CDMO stands for Contract Development and Manufacturing Organization — a company that provides both drug development and manufacturing services to pharma and biotech sponsors under contract.
What is the difference between a CDMO and a CMO?
A CMO (Contract Manufacturing Organization) only manufactures a product using a process the sponsor has already developed. A CDMO also handles development — formulation, process development, and analytical work — before manufacturing at scale.
How big is the CDMO market in 2026?
Estimates range from roughly $185 billion to $275 billion depending on the research firm and market definition, with a broad consensus around $270–275 billion, growing at 6–10% CAGR toward the early 2030s.
How does the BIOSECURE Act affect CDMO selection?
The BIOSECURE Act restricts US federal contracting with designated “biotechnology companies of concern,” expected to include several China-based CDMOs. While enforcement isn’t expected before late 2028, sponsors are already re-sourcing and diversifying supply chains ahead of the OMB designation list expected in late 2026.
How long does it take to switch CDMOs?
Switching typically requires facility and process requalification plus regulatory filings (such as a prior-approval supplement or IND amendment), which commonly takes 12–24 months — a key reason sponsors are advised to start dual-sourcing well ahead of any forced transition.
